News Release

Getting sticky with it: Phospholipid found to play a key role in epithelial cell adhesion

Phosphatidylinositol bisphosphate (PIP2) is essential for epithelial cell-cell adhesion and maintaining cellular identity

Peer-Reviewed Publication

Tokyo University of Science

Phospholipid PIP2 determines and maintains epithelial characteristics

image: The phospholipid PIP2 plays a critical role in maintaining the characteristics of epithelial cells. view more 

Credit: Yoshikazu Nakamura from Tokyo University of Science

In multicellular organisms, body cells adhere to each other to form tissues that perform various physiological functions. Epithelial cells form our skin and lining surfaces, such as the gut and other ducts, and protect our internal organs. To maintain the integrity of an organism and function properly, it is important for these cells to remain attached to each other. They do so through specific types of cellular junctions. These junctions are characterized by proteins, which also help in maintaining cellular identity. The loss of these proteins from cell surfaces causes them to lose their identity as epithelial cells, prompting their transformation into mesenchymal cells (through a process known as epithelial-mesenchymal transformation, or EMT), and subsequently, their progression towards cancer and fibrosis. These cancerous cells are only loosely adherent to each other (given that the proteins that helped maintain cellular adhesion are now lost), so they may separate from each other, migrate into the bloodstream, and cause the cancer to metastasize (spread to other parts of the body).

Now, while the role of proteins in maintaining cellular identity is well-researched, we can’t help but wonder–do lipids (fatty molecules) also play a role in characterizing cells and preventing EMT?

Under the guidance of Dr. Yoshikazu Nakamura and Dr. Kaori Kanemaru, researchers from Tokyo University of Science (TUS), Tokyo University of Pharmacy and Life Sciences, Tokyo Medical and Dental University, Akita University, Hokkaido University, and Kobe University have tried to find an answer to this question.

We know lipids are an important class of biomolecules, necessary for certain cellular functions. One such lipid, a phosphatidylinositol, forms a phospholipid called phosphatidylinositol bisphosphate (PIP2),” Associate Professor Dr. Nakamura from TUS dives into the topic. He tells us that PIP2 is important because it is crucial for the formation of signaling molecules that regulate cell proliferation, survival, and migration. “We had evidence that higher amounts of PIP2 were found in the epidermal layer of skin, so we hypothesized that this phospholipid contributed to the properties and characterization of epithelial cells.”

The findings from their study have been published in Nature Communications. The paper describes how the team used a battery of analytical techniques including chromatography, mass spectroscopy, immunofluorescence, retroviral expression, and real-time quantitative PCR to confirm that PIP2 plays a critical role in the determination of epithelial identity.

We saw that epithelial cells lost their properties when PIP2 was depleted from their cell membranes. On the other hand, osteosarcoma cells (which are cancerous, non-epithelial cells) gained epithelial cell-like properties when PIP2 was produced in their plasma membranes.” says Dr. Nakamura, with a look of excitement. The group was also able to show that PIP2 regulates these epithelial properties by recruiting Par3—a protein which guides vesicles intracellularly—to the plasma membrane. Once in the plasma membrane, Par3 facilitates the formation of adherens junctions (one of the cellular junctions discussed above) which anchor neighboring cells together. This partially prevents EMT, and hence, progression of cancer.

So,” Dr. Nakamura explains, “In theory, PIP2’s partial inhibition of EMT could halt cancer progression, making this phospholipid an attractive target molecule for anti-cancer treatment.”

TUS’ research has opened a new avenue for the development of anti-cancer drug development, possibly giving us a solution that will “stick.”

***

Reference

DOI: https://doi.org/10.1038/s41467-022-30061-9

 

About The Tokyo University of Science

Tokyo University of Science (TUS) is a well-known and respected university, and the largest science-specialized private research university in Japan, with four campuses in central Tokyo and its suburbs and in Hokkaido. Established in 1881, the university has continually contributed to Japan's development in science through inculcating the love for science in researchers, technicians, and educators.

With a mission of “Creating science and technology for the harmonious development of nature, human beings, and society", TUS has undertaken a wide range of research from basic to applied science. TUS has embraced a multidisciplinary approach to research and undertaken intensive study in some of today's most vital fields. TUS is a meritocracy where the best in science is recognized and nurtured. It is the only private university in Japan that has produced a Nobel Prize winner and the only private university in Asia to produce Nobel Prize winners within the natural sciences field.

Website: https://www.tus.ac.jp/en/mediarelations/

 

About Dr. Yoshikazu Nakamura from Tokyo University of Science

Dr. Yoshikazu Nakamura earned his Ph.D. in 2006 from the University of Tokyo and is an Associate Professor in the Department of Applied Biological Science at Tokyo University of Science. His lab conducts basic medical research tied to understanding the role of inositol lipids in skin diseases and cancer. He is currently coordinating research on the role of lipids in epithelial regulation and their importance in skin barrier formation. He is affiliated with the Japanese Biochemical Society and the Japanese Society for Investigative Dermatology and received Young Investigator Award from the Japanese Biochemical Society in 2016.

 

Funding information

The project was funded by a Grant-in-Aid for Scientific Research (B) 18H02575, the Takeda Science Foundation, the Sumitomo Foundation, the Terumo Life Science Foundation, the Mochida Memorial 1 Foundation for Medical and Pharmaceutical Research, the Ichiro Kanehara Foundation, the Hamaguchi Foundation for the Advancement of Biochemistry and PRIME to Y.N. and a Grant in-Aid for Young Scientists to Kaori Kanemaru.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.